Company news
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) news
Sensei Biotherapeutics, Inc. news releases on 6ix. Latest, Jun 13, 2023: Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista…
Press releases — page 2
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”
June 12, 2023
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
May 31, 2023
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 8, 2023
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
April 19, 2023
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
April 17, 2023
Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium
March 29, 2023
Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights
March 27, 2023
Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
March 20, 2023
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 13, 2023
Sensei Biotherapeutics Adopts Stockholder Rights Agreement
March 6, 2023
Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
March 5, 2023
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
February 20, 2023
Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit
February 15, 2023
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
February 13, 2023
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
February 5, 2023
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors
January 4, 2023
Sensei Biotherapeutics Provides Update on Strategic Priorities
December 7, 2022
Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
November 20, 2022
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 9, 2022
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 7, 2022
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint”
November 6, 2022
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
November 1, 2022
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 4, 2022
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
September 29, 2022
Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
September 20, 2022
Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody
August 30, 2022
Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 8, 2022
Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer
May 31, 2022
Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
May 24, 2022
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 9, 2022
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
March 9, 2022
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
March 8, 2022
Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
March 2, 2022
Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit
February 10, 2022
Sensei Biotherapeutics Announces Executive Promotions
January 5, 2022
Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award
December 15, 2021
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
December 12, 2021
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 11, 2021
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
November 8, 2021
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
November 2, 2021
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 30, 2021
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
August 3, 2021
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
August 1, 2021
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
June 27, 2021
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
May 18, 2021
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
May 11, 2021
Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board
May 4, 2021
Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors
April 4, 2021